John Carroll
The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. A lot of companies that develop biosimilars, and that group includes some major corporations, wanted to use the same generic–or nonproprietary–names as the branded drugs, looking to make it easier to carve their way into some blockbuster drug franchises. And a lot of those major brand name franchisors wanted something completely different, forcing the biosimilar crowd to market these drugs like a new arrival–a costly and time consuming affair that would help limit any discounting that may have to come after biosimilar competition hits.